Skip to main content
. 2017 Mar 15;8(26):42343–42358. doi: 10.18632/oncotarget.16216

Figure 4. Combination treatments with G1T38 in ER+ breast cancer and NSCLC.

Figure 4

G1T38 in combination with tamoxifen or fulvestrant (A), SERD (GW5638) (B), PI3K inhibitor (GDC0941) (C), for 28 days of treatment in ER+ breast cancer xenograft model (MCF7). (D) G1T38 single agent efficacy in NSCLC PDX model CTG-0159 after 28 days of daily 100 mg/kg oral treatment. (E, F) G1T38 in combination with oral EGFR inhibitors, erlotinib or afatinib, for 18 days of treatment in EGFR mutant NSCLC xenograft model (H1975). Statistics were completed using linear regression analysis of time during treatment. Error bars represent SEM. Yellow bar represents duration of treatment. **p≤0.01, ***p≤0.001, ****p≤0.0001.